S11 Ep36: HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
OncLive® On Air - Podcast készítő OncLive® On Air
Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.
